Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

March 01, 2023
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes
Read more
April 13, 2022
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis
Read more
March 14, 2022
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
Read more
January 13, 2022
Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study
Read more
November 03, 2021
Imcyse Appoints Gene Mack, MBA as Chief Financial Officer
Read more
June 24, 2021
Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth
Read more
June 24, 2021
INNODIA is ready for a new phase – clinical trials
Read more
February 17, 2021
Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round – Pfizer Joins as Newest Shareholder
Read more
February 03, 2021
Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis
Read more
February 03, 2021
Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
Read more

Events

Denis Bedoret

Chief Executive Officer

E info@imcyse.com

©imcyse 2023